Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07156578 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)

StatusEnrolling by Invitation
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv3
  2. Trial status: Not Yet Recruiting to Enrolling by Invitation Study sites: 0 to 9 · Start date changed from estimate of Nov 3, 2025 to Nov 10, 2025v2 Show 2 more changesShow less
    • Study sites: 0 to 9
    • Start date changed from estimate of Nov 3, 2025 to Nov 10, 2025
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a long-term, open-label extension study of bivamelagon in participants with Hypothalamic Obesity (HO) who have transitioned from the index study, LG-MCCL005. The study will last up to 2 years.
Trial Details
NCT Number NCT07156578
Lead Sponsor Rhythm Pharmaceuticals, Inc.
Conditions Hypothalamic Obesity
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov